Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Erythropoiesis-stimulating agents (ESAs) achieve hematological improvement-erythroid (HIE) in only 30% of ESA-naïve lower risk myelodysplastic syndrome (LR-MDS) patients with anemia, highlighting the need for developing novel drugs or new treatment strategies to improve the outcome of these patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Mei, Gaixiang Xu, Cuiping Zheng, Yaping Xie, Minming Li, Yanping Shao, Rongxin Yao, Shi Tao, Wei Jiang, Jun Guo, Zhiyin Zheng, Wei Wang, Xinping Zhou, Liya Ma, Li Ye, Yingwan Luo, Chunmei Yang, Wenjuan Yu, Wanzhuo Xie, Jie Jin, Hongyan Tong
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12102
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items